Objective
"TargED Biopharmaceuticals B.V. a spin-off from UMC Utrecht, is developing TGD001, an innovative first-in-class drug designed to treat all types of blood clots associated with thrombosis, a leading global cause of death that currently has limited effective treatments. TGD001 has shown superior results in preclinical studies, demonstrating high precision, safety, and efficacy, and TargED has raised over €45 million to fund its clinical trials, moving toward market readiness.
Unlike existing therapies, TGD001 has the ability to target both von Willebrand Factor (vWF) and fibrin, addressing the varied composition of blood clots. This dual-target mechanism enables TGD001 to effectively dissolve both macrovascular and microvascular clots, making it a ""one-drug-fits-all"" solution for thrombotic conditions. This comprehensive approach extends the treatment window, reduces bleeding risks, and makes it suitable for a wider range of patients compared to existing therapies.
TGD001 has received Orphan Drug Designation from the European Medicines Agency for thrombotic thrombocytopenic purpura (TTP), granting 10 years of market exclusivity, regulatory support, and financial incentives, significantly accelerating its development for immune Thrombotic Thrombocytopenic Purpura (iTTP), a rare and severe form of TTP.
Led by an experienced team, TargED is advancing TGD001 through clinical development, targeting iTTP and Acute Ischemic Stroke (AIS), indications on opposite ends of the clot composition spectrum, with global potential peak revenues of €421 million and €5.2 billion respectively. TargED’s core strategy is to advance TGD001 through to MAA/BLA submission independently. To further support the development, TargED plans a €25M Series B funding round to execute Phase 2a trials and a 1000L GMP manufacturing run to scale production. EIC funding is crucial to bridge the funding valley of death, accelerate clinical development, and ensure timely market entry and patient access.
"
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine angiology vascular diseases
- medical and health sciences basic medicine neurology stroke
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.1 - The European Innovation Council (EIC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-EIC-ACC - HORIZON EIC Accelerator
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIC-2025-ACCELERATOR-02
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
3584 CB UTRECHT
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.